Health Advance Files Updates to SEC for Most Recent Quarterly 10-Q Report

COLORADO SPRINGS, CO, Sept. 7, 2017 /PRNewswire/ - Health Advance Inc. (OTC PINKS: HADV) filed an amendment to the April 2017 quarterly report upon request from the SEC that was triggered by the, not so 180-degree transition in direction and executive management, which took place in June of this year.

Health Advance adopted a new roster of executive management in June, including seasoned physicians from Harvard University and Pfizer that are now contracted to take the Company into the future with research development and clinical trials to study alternative solutions to pharmaceutical drugs derived from opiates.

Despite some minor legal disputes with the former officer of the company in the U.S. civil court, the Company is making strides to continue works with government agencies and accredited research organizations to further the development of the patented product formulations of Polyoxyfen and Cebidiofen, two medical food product formulations derived from botanical extract blends of mitragyna speciosa (kratom), kava, and a regional regulatory program in the Micronesian Islands with ties to the U.S. for cannabidiol (CBD).

For more details about Health Advance go to www.hadvinc.com, or visit the company video overview at https://youtu.be/smJ_g-S7Cxo.

SOURCE Health Advance Inc.